10-Q quarterly report · filed Nov 5, 2026

Celldex Therapeutics, Inc. (CLDX) Q3 2026 10-Q Quarterly Report

Short answer

Celldex Therapeutics, Inc. (CLDX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$76M.

Q3 2026 key financials · XBRL

Revenue
$0
−100.0% QoQ
Net income
−$76M
−12.7% YoY · −2.8% QoQ
EPS (diluted)
−$0.95
+5.9% YoY · −2.2% QoQ

Source: XBRL data from the Celldex Therapeutics, Inc. (CLDX) Q3 2026 10-Q on SEC EDGAR. USD.

Celldex Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY from $0
  • Operating margin not meaningful, operating loss $82.3M vs $73.6M YoY
  • Barzolvolimab strongest program, Phase 3 CSU complete response up to 54.0% at Week 24
  • Cash, equivalents and marketable securities $650.3M; operating cash use $188.0M
  • BLA submission anticipated in 2027; higher barzolvolimab development costs expected near term

Risk Factors

  • No material changes identified in the provided Risk Factors section, which contains no substantive risk-factor disclosure
  • Liquidity risk: $650.3 million in cash, equivalents and marketable securities against $188.0 million operating cash burn
  • Financing risk: future $52.5 million milestone payment may require cash, stock or a combination
  • Regulatory risk: barzolvolimab remains subject to potential clinical-trial failure or regulatory approval delays
  • Marketable-securities risk: unrealized-loss positions increased to $576.5 million from $19.4 million

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Celldex Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.